[go: up one dir, main page]

PT3660073T - Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida - Google Patents

Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida

Info

Publication number
PT3660073T
PT3660073T PT192030716T PT19203071T PT3660073T PT 3660073 T PT3660073 T PT 3660073T PT 192030716 T PT192030716 T PT 192030716T PT 19203071 T PT19203071 T PT 19203071T PT 3660073 T PT3660073 T PT 3660073T
Authority
PT
Portugal
Prior art keywords
polymers
methods
low
burst
produce
Prior art date
Application number
PT192030716T
Other languages
English (en)
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of PT3660073T publication Critical patent/PT3660073T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08Lactones or lactides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/88Post-polymerisation treatment
    • C08G63/90Purification; Drying
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
PT192030716T 2007-02-15 2008-02-13 Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida PT3660073T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90143507P 2007-02-15 2007-02-15

Publications (1)

Publication Number Publication Date
PT3660073T true PT3660073T (pt) 2023-08-31

Family

ID=39504385

Family Applications (3)

Application Number Title Priority Date Filing Date
PT151852183T PT3202814T (pt) 2007-02-15 2008-02-13 Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
PT87255113T PT2115029E (pt) 2007-02-15 2008-02-13 Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
PT192030716T PT3660073T (pt) 2007-02-15 2008-02-13 Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT151852183T PT3202814T (pt) 2007-02-15 2008-02-13 Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
PT87255113T PT2115029E (pt) 2007-02-15 2008-02-13 Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros

Country Status (15)

Country Link
US (7) US9187593B2 (pt)
EP (3) EP3202814B1 (pt)
JP (3) JP5342459B2 (pt)
CA (1) CA2678350C (pt)
CY (2) CY1116785T1 (pt)
DK (3) DK2115029T3 (pt)
ES (3) ES2755374T3 (pt)
FI (1) FI3660073T3 (pt)
HR (3) HRP20150997T1 (pt)
HU (3) HUE047775T2 (pt)
LT (2) LT3202814T (pt)
PL (3) PL3202814T3 (pt)
PT (3) PT3202814T (pt)
SI (3) SI3660073T1 (pt)
WO (1) WO2008100532A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
WO2008153611A2 (en) * 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
CA2726763A1 (en) 2008-06-03 2009-12-10 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot composition
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
CN103421172B (zh) * 2012-05-23 2016-01-20 上海现代药物制剂工程研究中心有限公司 一种生物可降解聚酯的纯化工艺
AU2014249008B2 (en) 2013-03-11 2018-12-06 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP5959728B2 (ja) * 2013-04-11 2016-08-02 三井化学株式会社 乳酸―グリコール酸共重合体の製造法またはその塩の製造法
CN106132397A (zh) * 2013-12-06 2016-11-16 恩维希亚治疗股份有限公司 用于治疗眼部疾病的前房内植入物
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN108498456B (zh) * 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
KR20220041782A (ko) * 2019-05-27 2022-04-01 톨마 인터내셔날 리미티드 루프롤라이드 아세테이트 조성물 및 유방암 치료에 이용하는 방법
US20210251893A1 (en) 2020-02-06 2021-08-19 Ocular Therapeutix, Inc. Compositions and Methods for Treating Ocular Diseases
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
JP2023544311A (ja) 2020-09-30 2023-10-23 トルマー インターナショナル リミテッド テストステロンの延長送達のための生分解性ポリマー送達システム
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
WO2023027559A1 (ko) * 2021-08-27 2023-03-02 주식회사 엘지화학 블록 공중합체 및 이의 제조 방법
WO2024168022A2 (en) 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations
AU2024291054A1 (en) 2023-07-05 2025-11-27 Tolmar International Limited Polymeric leuprolide acetate formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DE3641692A1 (de) 1986-12-06 1988-06-09 Boehringer Ingelheim Kg Katalysatorfreie resorbierbare homopolymere und copolymere
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
DE69524398T2 (de) 1994-04-08 2002-07-18 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
JP4979843B2 (ja) 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP4317599B2 (ja) * 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
CN1195788C (zh) * 1997-10-03 2005-04-06 麦克罗梅德公司 具有可逆热胶凝性质的可生物降解低分子量三嵌段聚(丙交酯-共聚-乙交酯)聚乙二醇共聚物
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
ES2577389T3 (es) 2000-08-07 2016-07-14 Wako Pure Chemical Industries, Ltd. Polímero de ácido láctico y procedimiento para su producción
JP5188670B2 (ja) * 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
ES2528720T3 (es) * 2004-11-10 2015-02-12 Tolmar Therapeutics, Inc. Sistema de suministro de polímero estabilizado
DK2079767T3 (da) * 2006-10-11 2014-10-27 Tolmar Therapeutics Inc Fremstilling af bionedbrydelige polyestere med lave burst-egenskaber ved ekstraktion med et superkritisk fluid
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers

Also Published As

Publication number Publication date
PT2115029E (pt) 2015-10-26
WO2008100532A1 (en) 2008-08-21
HRP20192055T1 (hr) 2020-02-21
EP3660073B1 (en) 2023-07-12
US9187593B2 (en) 2015-11-17
US20160106847A1 (en) 2016-04-21
US20170095560A1 (en) 2017-04-06
CA2678350C (en) 2015-11-17
ES2755374T3 (es) 2020-04-22
PL2115029T3 (pl) 2016-01-29
US20100292195A1 (en) 2010-11-18
HUE047775T2 (hu) 2020-05-28
SI3660073T1 (sl) 2023-10-30
US11717572B2 (en) 2023-08-08
JP5848290B2 (ja) 2016-01-27
EP2115029B1 (en) 2015-09-16
JP5342459B2 (ja) 2013-11-13
PL3202814T3 (pl) 2020-01-31
DK2115029T3 (en) 2015-10-05
FI3660073T3 (fi) 2023-09-11
JP2010519218A (ja) 2010-06-03
JP2013224339A (ja) 2013-10-31
HK1138303A1 (en) 2010-08-20
HRP20150997T1 (hr) 2015-12-18
US10206970B2 (en) 2019-02-19
LT3202814T (lt) 2019-12-10
US20170216395A1 (en) 2017-08-03
PT3202814T (pt) 2019-11-26
ES2550014T3 (es) 2015-11-03
HRP20231117T3 (hr) 2023-12-22
SI2115029T1 (sl) 2016-01-29
EP3660073A1 (en) 2020-06-03
US9561282B2 (en) 2017-02-07
JP2015127351A (ja) 2015-07-09
DK3660073T3 (da) 2023-09-18
EP2115029A1 (en) 2009-11-11
HUE025842T2 (en) 2016-04-28
EP3202814B1 (en) 2019-10-16
US9655970B2 (en) 2017-05-23
US20220202941A1 (en) 2022-06-30
US9974824B2 (en) 2018-05-22
US11147880B2 (en) 2021-10-19
EP3202814A1 (en) 2017-08-09
US20190209643A1 (en) 2019-07-11
CY1122304T1 (el) 2021-01-27
HUE063170T2 (hu) 2024-01-28
CA2678350A1 (en) 2008-08-21
DK3202814T3 (da) 2019-11-25
PL3660073T3 (pl) 2023-12-27
ES2956244T3 (es) 2023-12-15
CY1116785T1 (el) 2017-03-15
JP6195587B2 (ja) 2017-09-13
LT3660073T (lt) 2023-10-10
SI3202814T1 (sl) 2019-12-31
US20180311305A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
PT3660073T (pt) Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida
IL210804A (en) Benzylidenehydrazides and their uses
ZA201007816B (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
ZA201100372B (en) Wounddressing and headgear
GB0711942D0 (en) Winglet
IL210153A0 (en) Nutrigenomics methods and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0808575D0 (en) Compilign and linking
GB0819530D0 (en) Methods and compositions
PT2362866E (pt) Compostos de isoprenila e métodos dos mesmos
GB0903299D0 (en) Composition and methods
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
ZA201104161B (en) Dihydroetorphines and their preparation
GB0800324D0 (en) Polymer and preparation process
GB0912744D0 (en) Methods and uses
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
EP2470022A4 (en) COMPOUNDS AND METHODS
GB0707069D0 (en) Methods and uses
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses
GB0722451D0 (en) Methods and uses
GB0707609D0 (en) Methods and uses
TWI366394B (en) Synchronnization devices and methods